Background: The Hisayama study is a prospective cohort study of lifestyle-related diseases that commenced in 1961. Through it, a significant increasing trend in the prevalence of Alzheimer’s disease has been observed over the past 18 years.
Objectives: We sought to investigate the increases in brain pathology related to Alzheimer’s disease using automated MATLAB morphometric analyses for quantifying tau pathology.
Methods: We examined a series of autopsied cases from Hisayama residents obtained between 1998 and 2003 (group A: 203 cases), and between 2009 and 2014 (group B: 232 cases). We developed custom software in MATLAB to analyze abnormal tau deposits quantitatively. Specimens were immunostained with both anti-amyloid-β-protein and anti-phosphorylated tau antibodies.
Results: Both the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) criteria for senile plaques and Braak stage for NFT were higher in group B. Morphometric analyses of the hippocampi also revealed a trend toward increased tau pathology in both men and women over 80 years of age in group B. The increases were also significant when the subjects were examined independently according to high or low CERAD scores and in all levels of AD neuropathologic change according to the National Institute on Aging-Alzheimer’s Association guidelines (2012).
Conclusion: We revealed a recent trend of increased tauopathy in the older people, which is partly independent of amyloid-β pathology.
PrinceM, WinoA, GuerchetM, AliGC, WuYT, PrinaM (2015) World Alzheimer Report 2015: The global impact of dementia, Alzheimer’s Disease International, London.
2.
MatsuzakiT, SasakiK, HataJ, HirakawaY, FujimiK, NinomiyaT, SuzukiSO, KanbaS, KiyoharaY, IwakiT (2011) Association of Alzheimer disease pathology with abnormal lipid metabolism: The Hisayama study. Neurology77, 1068–1075.
3.
MatsuzakiT, SasakiK, TanizakiY, HataJ, FujimiK, MatsuiY, SekitaA, SuzukiSO, KanbaS, KiyoharaY, IwakiT (2010) Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama study. Neurology75, 764–770.
4.
KuboM, HataJ, DoiY, TanizakiY, IidaM, KiyoharaY (2008) Secular trends in the incidence of and risk factors for ischemic stroke and its subtypes in Japanese community: The Hisayama study. Acta Psychiatr Scand122, 319–325.
5.
SekitaA, NinomiyaT, TanizakiY, DoiY, HataJ, YonemotoK, ArimaH, SasakiK, IidaM, IwakiT, KanbaS, KiyoharaY (2010) Trends in prevalence of Alzheimer’s disease and vascular dementia in a Japanese community: The Hisayama study. Acta Psychiatr Scand122, 319–325.
6.
KishimotoH, OharaT, HataJ, NinomiyaT, YoshidaD, MukaiN, NagataM, IkedaF, FukuharaM, KumagaiS, KanbaS, KitazonoT, KiyoharaY (2016) The long-term association between physical activity and risk of dementia in the community: The Hisayama study. Eur J Epidemiol31, 267–274.
7.
OharaT, NinomiyaT, HataJ, OzawaM, YoshidaD, MukaiN, NagataM, IwakiT, KitazonoT, KanbaS, KiyoharaY (2015) Midlife and late-life smoking and risk of dementia in the community: The Hisayama study. J Am Geriatr Soc63, 2332–2339.
8.
OzawaM, NinomiyaT, OharaT, DoiY, UchidaK, ShirotaT, YonemotoK, KitazonoT, KiyoharaY (2013) Dietary patterns and risk of dementia in an elderly Japanese population: The Hisayama study. Am J Clin Nutr97, 1076–1082.
9.
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd ed, revised. American Psychiatric Association, Washington, DC.
10.
BraakH, BraakE (1991) Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol1, 213–216.
11.
MirraSS, HeymanA, McKeelD, SumiSM, CrainBJ, BrownleeLM, VogelFS, HughesJP, van BelleG, BergL (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology41, 479–486.
BraakH, BraakE (1997) Diagnostic criteria for neuropathologic assessment of Alzheimer’s disease. Neurobiol Aging18, S85–S88.
14.
(1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer’s disease.S. Neurobiol Aging18, 1–2.
15.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersHV, MontineTJ (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
16.
McKeithIG, DicksonDW, LoweJ, EmreM, O’BrienJT, FeldmanH, CummingsJ, DudaJE, LippaC, PerryEK, AarslandD, AraiH, BallardCG, BoeveB, BurnDJ, CostaD, Del SerT, DuboisB, GalaskoD, GauthierS, GoetzCG, Gomez-TortosaE, HallidayG, HansenLA, HardyJ, IwatsuboT, KalariaRN, KauferD, KennyRA, KorczynA, KosakaK, LeeVM, LeesA, LitvanI, LondosE, LopezOL, MinoshimaS, MizunoY, MolinaJA, Mukaetova-LadinskaEB, PasquierF, PerryRH, SchulzJB, TrojanowskiJQ, YamadaM, Consortium on DLB (2005) diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology65, 1863–1872.
17.
FujimiK, SasakiK, NodaK, WakisakaY, TanizakiY, MatsuiY, SekitaA, IidaM, KiyoharaY, KanbaS, IwakiT (2008) Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: The Hisayama study. Brain Pathol18, 317–325.
18.
JainAK (1989) Fundamentals of digital image processing. Prentice Hall, New Jersey, pp. 68,71,73.
MacQueenJ (1967) Some methods for classification and analysis of multivariate observations. In Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, Volume 1: Statistics. University of California Press, Berkeley, pp. 281–297.
21.
PletnikovaO, WestN, LeeMK, RudowGL, SkolaskyRL, DawsonTM, MarshL, TroncosoJC (2005) Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging26, 1183–1192.
22.
HondaH, SasakiK, HamasakiH, ShijoM, KoyamaS, OharaT, NinomiyaT, KiyoharaY, SuzukiSO, IwakiT (2016) Trends in autopsy-verified dementia prevalence over 29 years of the Hisayama study. Neuropathology36, 383–387.
23.
SeshadriS, WolfPA, BeiserA, AuR, McNultyK, WhiteR, D’AgostinoRB (1997) Lifetime risk of dementia and Alzheimer’s disease. The impact of mortality on risk estimates in the Framingham study. Neurology49, 1498–1504.
24.
MungasD, TractenbergR, SchneiderJA, CranePK, BennettDA (2014) A 2-process model for neuropathology of Alzheimer’s disease. Neurobiol Aging35, 301–308.
ChibnikLB, ShulmanJM, LeurgansSE, SchneiderJA, WilsonRS, TranD, AubinC, BuchmanAS, HewardCB, MyersAJ, HardyJA, HuentelmanMJ, CorneveauxJJ, ReimanEM, EvansDA, BennettDA, De JagerPL (2011) CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol69, 560–569.
32.
DunnWDJr, GearingM, ParkY, ZhangL, HanfeltJ, GlassJD, GutmanDA (2016) Applicability of digital analysis and imaging technology in neuropathology assessment. Neuropathology36, 270–282.
33.
MurrayME, Graff-RadfordNR, RossOA, PetersenRC, DuaraR, DicksonDW (2011) Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: A retrospective study. Lancet Neurol10, 785–796.
34.
RobinsonJL, GeserF, CorradaMM, BerlauDJ, ArnoldSE, LeeVM, KawasCH, TrojanowskiJQ (2011) Neocortical and hippocampal amyloid-beta and tau measures associate with dementia in the oldest-old. Brain134, 3708–3715.
35.
WhitwellJL, DicksonDW, MurrayME, WeigandSD, TosakulwongN, SenjemML, KnopmanDS, BoeveBF, ParisiJE, PetersenRC, JackCRJr, JosephsKA (2012) Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: A case-control study. Lancet Neurol11, 868–877.
36.
ArmstrongRA, CairnsNJ (2009) Size frequency distribution of the beta-amyloid (abeta) deposits in dementia with Lewy bodies with associated Alzheimer’s disease pathology. Neurol Sci30, 471–477.
37.
NodaK, SasakiK, FujimiK, WakisakaY, TanizakiY, WakugawaY, KiyoharaY, IidaM, AizawaH, IwakiT (2006) Quantitative analysis of neurofibrillary pathology in a general population to reappraise neuropathological criteria for senile dementia of the neurofibrillary tangle type (tangle-only dementia): The Hisayama study. Neuropathology26, 508–518.
38.
SavvaGM, WhartonSB, IncePG, ForsterG, MatthewsFE, BrayneC (2009) Age, neuropathology, and dementia. N Engl J Med360, 2302–2309.
39.
MarshSE, Blurton-JonesM (2012) Examining the mechanisms that link beta-amyloid and alpha-synuclein pathologies. Alzheimers Res Ther4, 11.
40.
Colom-CadenaM, GelpiE, CharifS, BelbinO, BlesaR, MartiMJ, ClarimonJ, LleoA (2013) Confluence of alpha-synuclein, tau, and beta-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol72, 1203–1212.
41.
SatizabalCL, BeiserAS, ChourakiV, CheneG, DufouilC, SeshadriS (2016) Incidence of dementia over three decades in the Framingham heart study. N Engl J Med374, 523–532.
42.
MatthewsFE, StephanBC, RobinsonL, JaggerC, BarnesLE, ArthurA, BrayneC (2016) A two decade dementia incidence comparison from the cognitive function and ageing studies I and II. Nat Commun7, 11398.
43.
ChenR, HuZ, WeiL, MaY, LiuZ, CopelandJR (2011) Incident dementia in a defined older Chinese population. PLoS One6, e24817.
